Clarient Inc. (CLRT)

[B7$4]

"CLRT NEWS" New Data Indicate Effectiveness of Clarient's Pulmotax(TM) Test for Lung Cancer

http://www.prnewswire.com/news-releases/new-data-indicate-effectiveness-of-clarients-pulmotaxtm-test-for-lung-cancer-91686439.html

Pulmotax Identifies Patients Who Respond Positively to Chemotherapy

ALISO VIEJO, Calif., April 21 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled "TLE3 expression is predictive of response to chemotherapy in NSCLC," included 368 samples from carcinoma patients. The majority of advanced-stage patients who were treated with chemotherapy received a treatment regimen containing a taxane class agent.

Pulmotax is a single antibody immunohistochemistry test created to detect the expression of TLE3 in non-small cell lung cancer (NSCLC). Prior data have linked TLE3 expression specifically to response to taxane therapy in breast and ovarian carcinoma patients. The study was presented yesterday at the annual meeting of the American Association of Cancer Research (AACR) in Washington, D.C. by Douglas T. Ross, M.D., Ph.D., Chief Scientific O